TX-E2OPEN
9.8.2022 15:17:14 CEST | Business Wire | Press release
E2open Parent Holdings, Inc. (NYSE: ETWO), the connected supply chain SaaS platform with the largest multi-enterprise network, and Shippeo , a global leader in real-time multimodal transportation visibility, have expanded their partnership to provide clients with a new level of native real-time transportation visibility (RTTV) and supply chain execution management in a unified global platform.
Building on the success of the companies’ strategic partnership announced in 2020 , the newly expanded partnership unlocks additional value for clients by combining an unprecedented level of transportation visibility into e2open’s full range of supply chain planning and execution capabilities, for all modes and all geographies.
Industry-first unified experience for the modern, connected supply chain
Beyond simply alerting shippers to a transportation delay, the platform enables users to “peer” inside the truck or container to understand the specific goods being moved, how transportation performance will impact the customer experience, and most importantly, proactively take the best corrective action. This level of control at global scale enables enterprises to improve efficiency, reduce waste, and operate more sustainably across even the most complex global supply chains.
“We are thrilled to take our partnership with Shippeo to the next level to increase value for our clients, with the broadest and deepest real-time transportation visibility made available natively in e2open’s connected supply chain platform,” said Pawan Joshi, executive vice president, products and strategy for e2open. “Adding Shippeo’s visibility to e2open’s platform is a game-changer for the industry because it allows clients to remove data and decision silos, to drive efficiency and sustainability across the ecosystem of partners as they make, move, and sell products and services. Importantly, this expanded parternship creates shared value for shippers, carriers, and forwarders to foster a healthy, agile, and effective supply chain ecosystem.”
Shared value plus accurate and timely decision-making creates ROI for all parties
Shippeo’s unique carrier-first approach to real-time multimodal transportation visibility – honoring full compliance with global data management regulations, operating on a strict ‘need to know’ basis, and a commitment against developing freight matching solutions – has made it the RTTV of choice for carriers. This strategy has helped Shippeo earn the highest carrier onboarding satisfaction of 98% and has been the key to rapid expansion across geographies and modes. In addition, timely access to high-quality data results in higher-fidelity visibility as well as better predictive results, using innovative artificial intelligence and machine learning (AI/ML) algorithms. As a result, Shippeo is the only provider to guarantee ETA accuracy with a formal service-level agreement (SLA).
“Our expanded partnership with e2open offers transformative value to customers who will have not only real-time data and visibility to goods in motion, but also the control to take relevant action on one connected platform,” said Lucien Besse, chief operating officer and co-founder at Shippeo. “Our relentless focus on customer experience, carrier satisfaction, and exceptional data quality has helped us carve out a leadership position in the global real-time shipment visibility market. This approach has led us to expand our partnership with e2open. Further combining our in-transit visibility data with e2open’s ability to plan and execute addresses the ‘now what?’ when exceptions occur, while proactively avoiding disruptions before they occur, all from one connected platform."
For more information, visit www.e2open.com .
About Shippeo
Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more collaborative, automated, sustainable, profitable, and customer-centric supply chains. This is made possible with highly accurate, real-time operational visibility and perfect workflow orchestration. Their Multimodal Visibility Network integrates with more than 875 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and accurately measure CO2 and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Coca-Cola HBC, Carrefour, Renault Group, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 28 million shipments per year across 75 countries. Learn more at www.shippeo.com .
About e2open
E2open is the connected supply chain software platform that enables the world’s largest companies to transform the way they make, move, and sell goods and services. With the broadest cloud-native global platform purpose-built for modern supply chains, e2open connects more than 400,000 manufacturing, logistics, channel, and distribution partners as one multi-enterprise network tracking over 12 billion transactions annually. Our SaaS platform anticipates disruptions and opportunities to help companies improve efficiency, reduce waste, and operate sustainably. Moving as one.™ Learn More: www.e2open.com .
E2open and “Moving as one.” are the registered trademarks of E2open, LLC. All other trademarks, registered trademarks and service marks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220808005868/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release
Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
